Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions

  • Rubio, Miguel Ángel|||0000-0003-0735-6854
  • Cisa-Wieczorek, Sabina
  • Mozos, Ana|||0000-0002-3350-1827
  • Castellet, Helena
  • Bussaglia, Elena|||0000-0002-9237-731X
  • Carricondo, Maite
  • Hernández-Alvarez, María Isabel|||0000-0003-2483-7000
  • Sierra, Jorge|||0000-0002-7966-0356
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
Increased WT1 mRNA levels are pervasive in acute myeloid leukemia (AML), and this marker has been used to assess the leukemic compartment size after chemotherapy or hematopoietic cell transplants. Little is known about the effects of WT1 on the leukemic cells and their targets. This work used data obtained from gene expression arrays performed on AML samples with high and low WT1 mRNA levels to pinpoint genes that WT1 can regulate. We singled out SGK1, which showed an inverse correlation between its mRNA levels and WT1 in leukemic cell lines and AML samples. In cellular models, forced expression of WT1 reduced mRNA and protein levels of SGK1. Furthermore, WT1 repressed the SGK1 promoter activity, and accordingly, WT1 knockdown showed an increased expression of SGK1. We also detected an inverse correlation between WT1 and SGK1 during leukemic cell-line differentiation. WT1 genetic knockdown displayed decreased cell viability under nutrient deprivation. By contrast, SGK1 knockdown or pharmacologic inhibition increased resistance to apoptosis in response to serum starvation, acting on cell cycle progression. The effects of SGK1 targeting in hematologic conditions merit further investigation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CD200 in acute myeloid leukemia, marked upregulation in CEBPA biallelic mutated cases

  • González-Guerrero, L.
  • Castellet, Helena
  • Martínez, Clara
  • González, Nuria|||0000-0002-0087-5144
  • Guijarro, Francesca|||0000-0001-6376-0929
  • Lloveras, Natàlia|||0000-0002-9063-2241
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Gich, Ignasi|||0000-0003-3975-6588
  • Berenguer-Molins, Pau|||0000-0002-0170-2931
  • Perera-Bel, Júlia|||0000-0002-6809-132X
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Mascaró, Martí
  • Sampol, Antonia|||0000-0001-7465-6203
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Tormo, Mar|||0000-0001-9622-1649
  • Arnan, Montserrat
  • Villamor, Neus|||0000-0001-6538-4111
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
CD200 is a glycoprotein that binds with its receptor CD200R, providing immunosuppressive signals to T and NK cells. CD200 is expressed by normal stem cells and progenitors committed to B-lymphopoiesis and myeloid development. CD200 biological relevance in acute leukemias is only partially understood. The study included a consecutive series of four hundred thirty-one patients with acute myeloid leukemia (AML). Immunophenotype was established by multiparametric flow cytometry, and the genetic diagnosis was performed by PCR-based methods and a targeted resequencing method covering 42 genes. 66% of AML patients expressed CD200 being significantly associated with CD34 reactivity. The frequency of CD200 positivity was higher in cases with core-binding factor genetic lesions such as RUNX1-RUNX1T1 (81.3%) fusions and CBFB-MHY11 (63.2%) rearrangements and also with biallelic CEBPA mutations (100%). The molecular AML group with the lowest CD200 reactivity (19.1%) corresponded to AML with NPM1 mutations. RNA seq showed no uniform pattern of infiltrating cells in CEBPA mutated AML. Deconvolution analysis may be used to assess the immunoregulatory mechanisms of AML. CD200 expression could help identify the more immature compartment and, combined with other markers, single out CEPA-mutated AML.